Revenue
2010
2011
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $490.7M | $233.2M | $145.2M | $109.5M | $131.8M | $198.3M | $175.3M | $164.2M | $154.9M | $133.6M | $99.9M | $28.2M | $0 | — | $0 | $0 |
| Gross profit | $480.4M | $225.4M | $133.8M | $105.0M | $128.0M | $192.2M | $170.1M | $158.7M | $151.3M | $129.0M | $97.7M | $27.6M | $0 | — | −$12,000 | −$12,000 |
| Gross margin | 97.89% | 96.68% | 92.12% | 95.96% | 97.10% | 96.91% | 97.01% | 96.63% | 97.67% | 96.59% | 97.81% | 97.98% | — | — | — | — |
| Research & development | $206.0M | $217.5M | $245.0M | $227.3M | $201.2M | $131.8M | $141.0M | $123.8M | $78.2M | $70.8M | $50.4M | $47.8M | $7.1M | $662,502 | — | — |
| Operating expenses | $553.6M | $557.0M | $533.4M | $429.3M | $331.3M | $374.5M | $312.7M | $244.3M | $208.7M | $191.8M | $150.6M | $108.0M | $24.8M | $30.3M | $14,825 | $23,022 |
| Operating income | −$62.8M | −$323.8M | −$388.1M | −$319.8M | −$199.4M | −$176.2M | −$137.4M | −$80.0M | −$53.8M | −$58.2M | −$50.7M | −$79.8M | −$24.8M | −$30.3M | −$14,825 | −$23,022 |
| Operating margin | −12.80% | −138.88% | −267.24% | −292.17% | −151.27% | −88.83% | −78.34% | −48.73% | −34.72% | −43.58% | −50.80% | −282.98% | — | — | — | — |
| EBITDA | −$2.1M | −$280.3M | −$349.6M | −$299.1M | −$186.7M | −$151.6M | −$117.0M | −$61.4M | −$36.0M | −$42.1M | −$37.4M | −$74.4M | −$24.6M | −$30.1M | — | — |
| EBITDA margin | −0.42% | −120.20% | −240.71% | −273.25% | −141.60% | −76.43% | −66.70% | −37.37% | −23.23% | −31.50% | −37.40% | −263.83% | — | — | — | — |
| Net income | −$25.5M | −$321.5M | −$111.4M | −$278.5M | −$180.1M | −$169.4M | −$146.4M | −$102.7M | −$59.7M | −$47.9M | $117.2M | −$110.9M | −$34.6M | −$30.3M | −$14,825 | −$23,022 |
| Net profit margin | −5.21% | −137.90% | −76.70% | −254.41% | −136.60% | −85.43% | −83.51% | −62.51% | −38.55% | −35.86% | 117.36% | −393.36% | — | — | — | — |
| Basic EPSper basic share | -$0.29 | -$4.08 | -$1.50 | -$4.37 | -$3.01 | -$3.56 | -$3.46 | -$2.54 | -$1.54 | -$1.29 | $3.49 | -$4.43 | -$2.44 | -$8.29 | — | — |
| Diluted EPSper diluted share | -$0.29 | -$4.08 | -$1.50 | -$4.37 | -$3.01 | -$3.56 | -$3.46 | -$2.54 | -$1.54 | -$1.29 | $3.17 | -$4.43 | -$2.44 | -$8.29 | — | — |
Reported shareholders
| Holder | % owned |
|---|---|
Jupiter Topco LLC | 12.02%11.32M shares |
BlackRock, Inc. | 8.52%8.02M shares |
FMR LLC | 7.54%7.1M shares |
BANK OF AMERICA CORP /DE/ | 4.85%4.57M shares |
STATE STREET CORP | 4.52%4.26M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 4.36%4.11M shares |
PERCEPTIVE ADVISORS LLC | 3.98%3.75M shares |
NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | 2.99%2.81M shares |
ADAGE CAPITAL PARTNERS GP, L.L.C. | 2.73%2.57M shares |
GEODE CAPITAL MANAGEMENT, LLC | 2.52%2.37M shares |
Rock Springs Capital Management LP | 2.31%2.18M shares |
Kynam Capital Management, LP | 2.12%2M shares |
Stephens Investment Management Group LLC | 1.99%1.88M shares |
RENAISSANCE TECHNOLOGIES LLC | 1.95%1.83M shares |
EMERALD ADVISERS, LLC | 1.70%1.6M shares |
ARMISTICE CAPITAL, LLC | 1.67%1.57M shares |
TWO SIGMA INVESTMENTS, LP | 1.66%1.57M shares |
VANGUARD PORTFOLIO MANAGEMENT LLC | 1.64%1.54M shares |
GOLDMAN SACHS GROUP INC | 1.63%1.54M shares |
WELLINGTON MANAGEMENT GROUP LLP | 1.63%1.53M shares |
Percentages use 94.17M shares of this listed class outstanding on Jun 30, 2026.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 12, 2026Form 4 · 10b5-1 | Baynes Roy D.Director | SellCommon Stock | 4.5K | $50.00 | $225.0K | 41.5K |
| Jun 12, 2026Form 4 · 10b5-1 | Coughlin TimothyDirector | SellCommon Stock | 10.0K | $50.07 | $500.7K | 56.3K |
| May 15, 2026Form 4 · 10b5-1 | Coughlin TimothyDirector | SellCommon Stock | 3.3K | $43.49 | $141.3K | 52.3K |
| May 6, 2026Form 4 · 10b5-1 | Cline Christopher R.CHIEF FINANCIAL OFFICER | SellCommon Stock | 310 | $43.95 | $13.6K | 118.7K |
| May 6, 2026Form 4 · 10b5-1 | Inrig JulaCHIEF MEDICAL OFFICER | SellCommon Stock | 311 | $43.95 | $13.7K | 113.2K |